Role of B-cells in Mycosis Fungoides.
cutaneous T-cell lymphoma
mycosis fungoides
tumour microenvironment
B-cells
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
11 Mar 2021
11 Mar 2021
Historique:
pubmed:
10
3
2021
medline:
24
6
2021
entrez:
9
3
2021
Statut:
epublish
Résumé
Mycosis fungoides is the most common type of cutaneous T-cell lymphoma. The inflammatory micro-environment in mycosis fungoides is complex. There is accumulating evidence that the neoplastic T-cells take control of the microenvironment and thereby promote their own expansion by suppressing cellular immunity. B-cells have proved to be upregulated in large-cell transformed mycosis fungoides, and could potentially play a role in disease progression. To investigate the presence of B-cells in mycosis fungoides compared with controls, this study analysed 85 formalin-fixed and paraffin-embedded mycosis fungoides biopsies. MS4A1 gene expression was significantly upregulated in mycosis fungoides compared with controls (p < 0.0001) and further upregulated in disease progression, (p = 0.001). Digital quantification of PAX5+/CD20+ cells confirmed the increased presence of B-cells in mycosis fungoides compared with controls. No co-labelling of CD3/CD20 was observed in the neoplastic T-cells. This study found a significantly increased presence of B-cells in the tumour-associated microenvironment in mycosis fungoides. These findings could potentially lead to new treatment strategies for mycosis fungoides.
Identifiants
pubmed: 33686443
doi: 10.2340/00015555-3775
pmc: PMC9366504
doi:
Substances chimiques
Antigens, CD20
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00413Références
Oncotarget. 2015 Aug 21;6(24):20555-69
pubmed: 26244872
Blood. 2009 Jun 4;113(23):5896-904
pubmed: 19351960
J Allergy Clin Immunol. 2016 Jan;137(1):118-129.e5
pubmed: 26441226
Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):387-92
pubmed: 18528277
J Dermatol. 2014 Jan;41(1):11-8
pubmed: 24438139
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
J Clin Oncol. 2016 Apr 20;34(12):e110-6
pubmed: 25348001
Eur J Dermatol. 2018 Jun 1;28(3):314-319
pubmed: 29952298
Int Immunol. 2015 Oct;27(10):495-504
pubmed: 25957264
Blood. 2019 Sep 26;134(13):1072-1083
pubmed: 31331920
Br J Dermatol. 2007 Aug;157(2):284-9
pubmed: 17573879
Eur J Dermatol. 2016 Dec 1;26(6):566-571
pubmed: 27545221
Blood. 2011 Nov 24;118(22):5891-900
pubmed: 21865341
Blood. 2000 Apr 1;95(7):2212-8
pubmed: 10733487
Semin Immunopathol. 2017 Apr;39(3):269-282
pubmed: 27717961
Br J Dermatol. 2008 Jul;159(1):105-12
pubmed: 18489588
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
Nat Genet. 2015 Dec;47(12):1465-70
pubmed: 26551667
J Clin Rheumatol. 2018 Dec;24(8):427-435
pubmed: 29561469
Cancer Res. 2011 May 15;71(10):3505-15
pubmed: 21444674
Blood. 2007 Sep 15;110(6):1713-22
pubmed: 17540844
Nat Genet. 2015 Sep;47(9):1011-9
pubmed: 26192916
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Cancer Immunol Immunother. 2011 May;60(5):609-19
pubmed: 21253724
Br J Dermatol. 2017 Sep;177(3):791-800
pubmed: 28256712
Acta Derm Venereol. 2019 Dec 1;99(13):1231-1236
pubmed: 31620804
Blood. 2012 Feb 16;119(7):1643-9
pubmed: 22160616
Ann Rheum Dis. 2012 Nov;71(11):1868-71
pubmed: 22833373
Am J Dermatopathol. 1989 Dec;11(6):509-16
pubmed: 2604018
Am J Surg Pathol. 2013 Dec;37(12):1845-54
pubmed: 24145652
Anticancer Res. 2014 Dec;34(12):7207-17
pubmed: 25503151
J Allergy Clin Immunol. 2008 Jan;121(1):122-8
pubmed: 18206507
Nat Genet. 2015 Sep;47(9):1056-60
pubmed: 26258847
Am J Dermatopathol. 2009 Dec;31(8):814-8
pubmed: 19786854
Toxins (Basel). 2013 Aug 14;5(8):1402-21
pubmed: 23949004
Blood. 2015 Jul 23;126(4):508-19
pubmed: 26082451
J Invest Dermatol. 2021 Jan;141(1):213-217.e5
pubmed: 32454067
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Blood. 2007 Oct 15;110(8):3015-27
pubmed: 17638852